Evidence map›Paper›PMID 38025464›Full record

ReviewFrontiers in psychiatry2023

Leveraging iPSC technology to assess neuro-immune interactions in neurological and psychiatric disorders.

Christina Michalski, Zhexing Wen

Abstract readReview
In one paragraph

Review in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christina MichalskiDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States.
Zhexing WenDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States.

Funding

Understanding the functional impacts of Aβ variants in Alzheimer's disease with human brain organoidsRF1AG079256 · NIA · EMORY UNIVERSITY · PI BOMMARIUS, ANDREAS S, LIANG, BO · 2022 to 2025
$4.1M
Towards a better understanding of genetic architecture of Alzheimer's disease with human iPSC modelsR01AG065611 · NIA · EMORY UNIVERSITY · PI LI, BINGSHAN, WEN, ZHEXING · 2020 to 2024
$3.8M
Using Human iPSC Models to Determine the Mechanism of Inflammation-Induced Disruption of Dopamine NeurotransmissionR21MH132012 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H, WEN, ZHEXING · 2022 to 2023
$430k
Towards a Better Understanding of Fragile X Syndrome Using Human Brain OrganoidsR21MH123711 · NIMH · EMORY UNIVERSITY · PI WEN, ZHEXING · 2020 to 2020
$429k
NIA NIH HHS R01 AG065611NIA NIH HHS RF1 AG079256NIMH NIH HHS R21 MH123711NIMH NIH HHS R21 MH132012
6 · The paper itself

Abstract

Communication between the immune and the nervous system is essential for human brain development and homeostasis. Disruption of this intricately regulated crosstalk can lead to neurodevelopmental, psychiatric, or neurodegenerative disorders. While animal models have been essential in characterizing the role of neuroimmunity in development and disease, they come with inherent limitations due to species specific differences, particularly with regard to microglia, the major subset of brain resident immune cells. The advent of induced pluripotent stem cell (iPSC) technology now allows the development of clinically relevant models of the central nervous system that adequately reflect human genetic architecture. This article will review recent publications that have leveraged iPSC technology to assess neuro-immune interactions. First, we will discuss the role of environmental stressors such as neurotropic viruses or pro-inflammatory cytokines on neuronal and glial function. Next, we will review how iPSC models can be used to study genetic risk factors in neurological and psychiatric disorders. Lastly, we will evaluate current challenges and future potential for iPSC models in the field of neuroimmunity.

Indexed as

induced pluripotent stem cellsmicroglianeurodegenerative disordersneurodevelopmentneuroimmunitypsychiatric disorders

Identifiers

PMID38025464
PMCPMC10672983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.